新型冠状病毒变异株的演化与研究进展

何军; 罗婉蓉; 夏艺丹; 吴家兵

doi:10.19837/j.cnki.ahyf.2023.04.012

PDF(1058 KB)

安徽预防医学杂志 ›› 2023, Vol. 29 ›› Issue (4) : 317-323. DOI: 10.19837/j.cnki.ahyf.2023.04.012

综述

新型冠状病毒变异株的演化与研究进展

何军^1,2,3, 罗婉蓉^1,2, 夏艺丹³, 吴家兵¹

作者信息 +

Evolution and research progress of SARS-CoV-2 variants

HE Jun^1,2,3, LUO Wanrong^1,2, XIA Yidan³, WU Jiabing¹

Author information +

文章历史 +

摘要

新型冠状病毒(SARS-CoV-2)具有高突变率,在全球范围内广泛流行,其变异株也在全世界蔓延。SARS-CoV-2刺突蛋白的突变会增加病毒的传播速度和疾病严重程度,增强病毒逃逸宿主免疫保护反应、单克隆抗体治疗或现有疫苗的保护效力的能力。本综述按照世界卫生组织(WHO)对SARS-CoV-2的分类定义与追踪监测,系统归纳了其变异株的演化过程和应对措施,为进一步做好新型冠状病毒感染防控提供科学依据。

Abstract

The disease caused by the SARS-CoV-2 virus has been widespread worldwide,associated by its high mutation rate.The virus variants have been constantly spreading around the world,too.Mutations in the spike protein of SARS-CoV-2 can increase the transmission efficiency and the severity of the disease,meanwhile these mutations can enhance the ability of the virus to evade either the immune protective responses,monoclonal antibody treatments,or the efficacy of current licensed vaccines.According to the WHO’s working definitions and tracking system for SARS-CoV-2,this review systematically summarizes the evolution of SARS-CoV-2 variants,providing scientific basis for further prevention and control of COVID-19.

导出引用

何军, 罗婉蓉, 夏艺丹, 吴家兵. 新型冠状病毒变异株的演化与研究进展[J]. 安徽预防医学杂志. 2023, 29(4): 317-323 https://doi.org/10.19837/j.cnki.ahyf.2023.04.012

HE Jun, LUO Wanrong, XIA Yidan, WU Jiabing. Evolution and research progress of SARS-CoV-2 variants[J]. Anhui Journal of Preventive Medicine. 2023, 29(4): 317-323 https://doi.org/10.19837/j.cnki.ahyf.2023.04.012

中图分类号： R372

参考文献

[1] Liu Z,Xiao X,Wei X,et al.Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2[J].J Med Virol,2020,92(6):595-601.
[2] Thomas S.Mapping the nonstructural transmembrane proteins of severe acute respiratory syndrome coronavirus 2[J].J Comput Biol,2021,28(9):909-921.
[3] Naqvi AAT,Fatima K,Mohammad T,et al.Insights into SARS-CoV-2 genome,structure,evolution,pathogenesis and therapies:structural genomics approach[J].Biochim Biophys Acta Mol Basis Dis,2020,1866(10):165878.
[4] Wang Q,Zhang Y,Wu L,et al.Structural and functional basis of SARS-CoV-2 entry by using human ACE2[J].Cell,2020,181(4):894-904.
[5] Huang SW,Wang SF.SARS-CoV-2 entry related viral and host genetic variations:implications on COVID-19 severity,immune escape,and infectivity[J].Int J Mol Sci,2021,22(6):3060.
[6] Padhi AK,Tripathi T.Can SARS-CoV-2 accumulate mutations in the S-protein to increase pathogenicity?[J].ACS Pharmacol Transl Sci,2020,3(5):1023-1026.
[7] Volz E,Hill V,McCrone JT,et al.Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity[J].Cell,2021,184(1):64-75.
[8] World Health Organization.Weekly epidemiological update on COVID-19-16 March 2023.[EB/OL].(2023-05-18)[2023-03-21].https://www.who.int/activities/tracking-SARS-CoV-2-variants.
[9] Wang D,Zhou B,Keppel TR,et al.N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry[J].Sci Rep,2021,11(1):23561.
[10] Zhou B,Thao TTN,Hoffmann D,et al.SARS-CoV-2 spike D614G change enhances replication and transmission[J].Nature,2021,592(7852):122-127.
[11] Plante JA,Liu Y,Liu J,et al.Spike mutation D614G alters SARS-CoV-2 fitness[J].Nature,2021,592(7852):116-121.
[12] Washington NL,Gangavarapu K,Zeller M,et al.Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States[J].Cell,2021,184(10):2587-2594.
[13] Volz E,Mishra S,Chand M,et al.Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England[J].Nature,2021,593(7858):266-269.
[14] Kemp SA,Collier DA,Datir RP,et al.SARS-CoV-2 evolution during treatment of chronic infection[J].Nature,2021,592(7853):277-282.
[15] Lista MJ,Winstone H,Wilson HD,et al.The P681H mutation in the spike glycoprotein of the Alpha variant of SARS-CoV-2 escapes IFITM restriction and Is necessary for type I interferon Resistance[J].J Virol,2022,96(23):e0125022.
[16] Abu-Raddad LJ,Chemaitelly H,Yassine HM,et al.Pfizer-BioNTech mRNA BNT162b2 COVID-19 vaccine protection against variants of concern after one versus two doses[J].J Travel Med,2021,28(7):taab083.
[17] Liu C,Zhou D,Nutalai R,et al.The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants[J].Cell Host Microbe,2022,30(1):53-68.
[18] Wang P,Nair MS,Liu L,et al.Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7[J].Nature,2021,593(7857):130-135.
[19] Madhi SA,Baillie V,Cutland CL,et al.Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant[J].N Engl J Med,2021,384(20):1885-1898.
[20] Maggi F,Novazzi F,Genoni A,et al.Imported SARS-CoV-2 variant P.1 in traveler returning from Brazil to Italy[J].Emerg Infect Dis,2021,27(4):1249-1251.
[21] Hayawi K,Shahriar S,Serhani MA,et al.Vaccine versus variants (3Vs):Are the COVID-19 vaccines effective against the variants? A systematic review[J].Vaccines(Basel),2021,9(11):1305.
[22] Huang HC,Liao CC,Wang SH,et al.Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis[J].Am J Cancer Res,2021,11(10):4994-5005.
[23] Singanayagam A,Hakki S,Dunning J,et al.Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK:a prospective,longitudinal,cohort study[J].Lancet Infect Dis,2022,22(2):183-195.
[24] Starr TN,Czudnochowski N,Liu Z,et al.SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape[J].Nature,2021,597(7874):97-102.
[25] Liu Y,Liu J,Johnson BA,et al.Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant[J].Cell Rep,2022,39(7):110829.
[26] Deng X,Garcia-Knight MA,Khalid MM,et al.Transmission,infectivity,and neutralization of a spike L452R SARS-CoV-2 variant[J].Cell,2021,184(13):3426-3437.
[27] McCallum M,Bassi J,De Marco A,et al.SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern[J].Science (New York,N.Y.),2021,373(6555):648-654.
[28] Zhang L,Cui Z,Li Q,et al.Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity,animal tropism,and antibody neutralization[J].Commun Biol,2021,4(1):1196.
[29] Annavajhala MK,Mohri H,Wang P,et al.Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York[J].Nature,2021,597(7878):703-708.
[30] Zhou H,Dcosta BM,Samanovic MI,et al.B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies[J].mBio,2021,12(4):e0138621.
[31] Singh J,Malhotra AG,Biswas D,et al.Relative consolidation of the Kappa variant Pre-Dates the massive second wave of COVID-19 in India[J].Genes,2021,12(11):1803.
[32] Ren W,Ju X,Gong M,et al.Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa),B.1.617.2 (Delta),and B.1.618 by cell entry and immune evasion[J].mBio,2022,13(2):e0009922.
[33] Yang X,Zhu Y,Xun J,et al.The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines[J].iScience,2022,25(9):105016.
[34] Yang Y,Zang J,Xu S,et al.Elicitation of broadly neutralizing antibodies against B.1.1.7,B.1.351,and B.1.617.1 SARS-CoV-2 variants by three prototype strain-derived recombinant protein vaccines[J].Viruses,2021,13(8):1421.
[35] Kimura I,Kosugi Y,Wu J,et al.The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance[J].Cell Rep,2022,38(2):110218.
[36] Chatterjee D,Tauzin A,Laumaea A,et al.Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes[J].Viruses,2022,14(1):144.
[37] Álvarez-Díaz DA,Muñoz AL,Tavera-Rodríguez P,et al.Low neutralizing antibody titers against the Mu variant of SARS-CoV-2 in 31 BNT162b2 vaccinated individuals in Colombia[J].Vaccines,2022,10(2):180.
[38] Halfmann PJ,Kuroda M,Armbrust T,et al.Characterization of the SARS-CoV-2 B.1.621 (Mu) variant[J].Sci Transl Med,2022,14(657):eabm4908.
[39] Ren SY,Wang WB,Gao RD,et al.Omicron variant (B.1.1.529) of SARS-CoV-2:mutation,infectivity,transmission,and vaccine resistance[J].World J Clin Cases,2022,10(1):1-11.
[40] Shin DH,Smith DM,Choi JY.SARS-CoV-2 Omicron variant of concern:everything you wanted to know about Omicron but were afraid to ask[J].Yonsei Med J,2022,63(11):977-983.
[41] Wang L,Cheng G.Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa[J].J Med Virol,2022,94(4):1728-1733.
[42] Zhao H,Lu L,Peng Z,et al.SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells[J].Emerg Microbes Infect,2022,11(1):277-283.
[43] Nyberg T,Ferguson NM,Nash SG,et al.Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England:a cohort study[J].Lancet,2022,399(10332):1303-1312.
[44] Sheikh A,Kerr S,Woolhouse M,et al.Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II):a national cohort study with nested test-negative design[J].Lancet Infect Dis,2022,22(7):959-966.
[45] Andrews N,Stowe J,Kirsebom F,et al.COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) Variant[J].N Engl J Med,2022,386(16):1532-1546.
[46] Takashita E,Kinoshita N,Yamayoshi S,et al.Efficacy of antibodies and antiviral drugs against COVID-19 Omicron variant[M].Online:N Engl J Med,2022:995-998.
[47] Wilder-Smith A,Chiew CJ,Lee VJ.Can we contain the COVID-19 outbreak with the same measures as for SARS?[J].Lancet Infect Dis,2020,20(5):e102-e107.
[48] Kaushik A.Manipulative magnetic nanomedicine:the future of COVID-19 pandemic/endemic therapy[M].Expert Opin Drug Deliv,2021:531-534.
[49] Shah MM,Joyce B,Plumb ID,et al.Paxlovid associated with decreased hospitalization rate among adults with COVID-19-United States,April-September 2022[J].MMWR Morb Mortal Wkly Rep,2022,71(48):1531-1537.
[50] Gog JR,Hill EM,Danon L,et al.Vaccine escape in a heterogeneous population:insights for SARS-CoV-2 from a simple model[J].R Soc Open Sci,2021,8(7):210530.
[51] Assmus LM,Guan J,Wu T,et al.Overlapping peptides elicit distinct CD8 + T cell responses following influenza a virus infection[J].J Immunol,2020,205(7):1731-1742.
[52] 郭倩,黄明月,龚磊,等.新型冠状病毒肺炎最新研究进展[J].安徽预防医学杂志,2022,28(3):234-238+254.